PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Gilead and Novo Nordisk’s NASH trial meets primary endpoint

Gilead and Novo Nordisk have announced that a phase II proof-of-concept trial evaluating combination treatments for non-alcoholic steatohepatitis (NASH) met its primary endpoint.

The five-arm trial evaluated combinations of Novo’s semaglutide – a GLP-1 receptor agonist – with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor firsocostat over 24 weeks.

The results, which were presented at The Liver Meeting Digital Experience 2020, showed that the trial met the primary endpoint by demonstrating that all regimens were well tolerated in people with NASH and mild to moderate fibrosis.

In addition, exploratory efficacy endpoints, which assessed biomarkers of liver health at 24 weeks, showed ‘statistically significant improvements’ in hepatic steatosis and liver injury in the combination arms compared to semaglutide alone.

Semaglutide is used in Novo’s once-weekly injection for type 2 diabetes Ozempic, as well as its once-daily type 2 diabetes pill Rybelsus.

The companies also said that although semaglutide significantly improved NASH and fibrosis-related endpoints in the trial, the addition of either cilofexor or the firsocostat analog improved liver reduction further.

NASH is a chronic liver disease characterised by fat accumulation and inflammation in the liver, which can cause scarring – fibrosis – that negatively impacts liver function.

“This trial brings together Gilead and Novo Nordisk’s respective expertise and science to provide important insights into potential new combination therapies involving semaglutide to help people living with NASH,” said Martin Holst Lange, senior vice president, global development at Novo Nordisk.

“We are now carefully evaluating next steps together based on a thorough assessment of data,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026